Enhertu meets main goal in phase 3 lung cancer trial
Tweet Send to a Friend
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) said their cancer drug Enhertu (trastuzumab deruxtecan) met the primary endpoint in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
